Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Earnings call: Stevanato Group sustains growth momentum in Q3 2023, reiterates full-year guidance

Published Nov 01, 2023 08:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
STVN
+5.04%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Stevanato Group has announced an 11% revenue increase to EUR271.4 million in Q3 2023, propelled by growth across its segments. Despite the Engineering Segment's revenue falling short of expectations due to timing issues, the company remains optimistic about achieving its full-year guidance. The company's core Drug Containment Solutions (DCS) business grew by 10% in Q3 compared to the same period last year. The company also discussed its current order backlog and forward visibility, extending into fiscal year 2025.

Key takeaways from the call:

  • The company's growth was driven by both segments, with a notable 10% increase in the core Drug Containment Solutions (DCS) business.
  • The company reiterated its full-year 2023 guidance, expecting revenue in the range of EUR1,085 million to EUR1,115 million and adjusted EBITDA in the range of EUR291.8 million to EUR303.8 million.
  • The company's investments in capacity expansion are aimed at meeting the demand for high-performance drug containment.
  • The revenue from new business opportunities in the Drug Delivery System space is expected to materialize in the second half of 2025.
  • The company's order backlog extends into fiscal year 2025, providing strong visibility for future demand.
  • The company expects to increase its gross profit margin in the BDS segment compared to the previous year, while the engineering segment will see a slight decline.

Stevanato Group (EXCHANGE:STVN) operates in growing markets, particularly biologics, and has a strong presence in areas such as GLP1, monoclonal antibodies, and mRNA applications. The global pipeline of drugs in development is also at record levels, with a focus on injectable formats. The company is focused on executing strategic priorities to deliver sustainable organic growth and build shareholder value.

The company's in vitro diagnostics business has been slower to recover from the pandemic, but it expects normalization over the next few quarters. This business is seen as a strategic foothold to diversify into Drug Delivery System activities.

In the earnings call, the company also clarified that the change in order visibility is due to the nature of contracts rather than customers ordering far in advance. They also highlighted the increasing number of customers using multiple product lines and their focus on being a solution provider.

The company stated that they are not experiencing destocking in the Drug Containment Solutions segment and that they need to expand capacity to meet strong demand. The call concluded with no further questions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Earnings call: Stevanato Group sustains growth momentum in Q3 2023, reiterates full-year guidance
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email